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Sarcomas are rare tumours of the connective tissue which
may resemble a variety of tissues – such as muscle, nerve
and bone – although many sarcomas have no normal tis-
sue counterpart. The annual incidence of soft-tissue sarco-
mas (STSs) in England and Wales between 1990 and 2007
was 2300, which equates to about 40 per million per an-
num. Bone sarcomas are significantly less common, repre-
senting only 0.2% of all malignancies. Treatment within
specialised multidisciplinary teams (MDTs) is crucial since
a body of expertise in all areas of diagnosis and treatment
is required to manage them appropriately. Studies have
shown that conformity to approved treatment guidelines
is improved when patients are treated by an MDT in a ref-
erence centre [1].
2. Diagnosis – histopathology, radiology
The risk of a tumour being metastatic at diagnosis, and
of subsequent death, is directly related to tumour size
[2]. Earlier diagnosis could have a huge impact, and guide-
lines are now in place in the UK to encourage early refer-
ral of suspicious lumps (or X-rays in the case of bone
tumours).
Once a tumour is suspected, the two key diagnostic
tools are radiology and histopathology. The initial assess-
ment of suspicious lumps will be by physical examina-
tion and probably ultrasound, followed by core needle
biopsy. Core needle biopsy has an accuracy of >90% as
well as the ability to distinguish high-grade from low-
grade lesions and in most cases the specific sarcoma
subtype [3].
Cross-sectional imaging is required prior to surgery,
in order to plan treatment and for staging. This is
usually in the form of magnetic resonance imaging
(MRI) for the primary disease site and computed
tomography (CT) for staging purposes. It is commonfor the diagnosis of patients referred with a diagnosis
of sarcoma to be revised to another subtype, another
disease, or even a benign condition [4]. Reported dis-
crepancy rates between referring and expert patholo-
gists are generally in the order of 25%, with a
benign to malignant discrepancy of 5%.
3. Sarcoma surgery
The primary management of most sarcomas is surgical
excision. Unplanned operations, performed on the
assumption that the ‘‘lump’’ is benign, can make the
eradication of disease much more difficult. A study dem-
onstrated that patients who had unplanned surgery had
a much higher local recurrence rate and poorer long-
term disease control, in spite of definitive surgery and
radiotherapy [5]. All sarcoma operations should be per-
formed in specialised centres in order to ensure opti-
mum outcomes. For retroperitoneal surgery, where
multivisceral resections are common, guidance is avail-
able [6]. The NICE (National Institute for Health and
Care Excellence) Improving Outcomes Guidance (IOG) for
people with sarcoma recommended that specialised cen-
tres should treat a minimum of 100 STS a year and 50
in the case of bone sarcomas. The IOG, which also ad-
dresses wider issues concerning the sarcoma MDT, can
be obtained using the following URL: http://guid-
ance.nice.org.uk/CSG
4. Radiation oncology
Adjuvant radiotherapy improves the local control of high-
grade extremity soft tissue sarcomas [7]. Research continues
into the appropriate timing, dose and field size of adjuvant
irradiation. The complexity of pre- and post-operative radio-
therapy for sarcomas is such that specialised centres are best
placed to offer the appropriate expertise, in the context of the
MDT.
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Chemotherapy for most sarcomas is palliative, but never-
theless valuable. Recent years have seen a significant in-
crease in treatment options and tailoring of treatment to
the individual disease subtype. The standard agents, doxo-
rubicin and ifosfamide, remain useful, but other drugs are
now in routine use, including gemcitabine plus docetaxel
for leiomyosarcoma and pleomorphic sarcoma [8,9], tra-
bectedin for leiomyosarcoma and liposarcoma [10] and
paclitaxel for angiosarcoma [11]. The management of gas-
trointestinal stromal tumour (GIST) was transformed by
the introduction of imatinib [12,13], and subsequently sun-
itinib [14]. More recently another tyrosine kinase inhibitor,
pazopanib, has been licensed for treatment of STS [15].
Certain rarer diseases require special approaches: e.g. the
use of rapamycin analogues for PEComa, imatinib for
chordoma, tamoxifen for fibromatosis and aromatase
inhibitors for endometrial stromal sarcoma.
6. Clinical trials and data collection
Clearly, for such a rare group of diseases it is essential that
care be concentrated in specialised centres which can treat
patients in appropriate clinical trials. These will not be avail-
able in smaller centres, putting patients at a disadvantage.
The cumulative experience of the MDT together with the
amalgamation of clinical and laboratory data also represent
a major resource for research and the opportunity to use
these data directly for the benefit of patients.
7. The wider multidisciplinary team
In addition to surgeons, radiation and medical oncologists,
radiologists and histopathologists, the MDT will have clinical
nurse specialists, physiotherapists, dieticians, palliative care
physicians and site-specific specialists.
As described, the management of sarcomas is truly multi-
disciplinary, increasingly complex and, as more molecular
targets are identified, more likely to be treated with highly
specific targeted therapy. The need for specialised centres
has been recognised in the UK, and a process, informed by
the NICE IOG, is leading to the concentration of care in a lim-
ited number of centres. We hope that earlier diagnosis, fewer
unplanned operations and better integrated care will lead to a
significant improvement in outcomes, which have not chan-
ged over the last 20 years (http://www.ncin.org.uk/publica-
tions/data_briefings/soft_tissue_sarcoma). We can only hope
to do better.
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